IDEXX Laboratories: Premium Quality, Premium Price – Best-in-Class Veterinary Diagnostics Facing Growth and Valuation Tests
IDEXX Laboratories, Inc. (IDXX) stands as the undisputed global sovereign of the veterinary diagnostics and software ecosystem, a sector characterized by durable secular growth, high barriers to entry, and a unique emotional undercurrent driven by the "humanization of pets." As of late 2025, the company continues to operate as the central nervous system for veterinary clinics worldwide, providing a tightly integrated suite of in-clinic diagnostic analyzers, reference laboratory services, and practice management software. This proprietary ecosystem creates a formidable economic moat, characterized by high switching costs and a recurring revenue model that mimics the financial profile of a top-tier Software-as-a-Service (SaaS) enterprise, despite its heavy reliance on physical hardware and laboratory infrastructure.
The investment narrative for IDEXX has historically been defined by its ability to deliver "sector-plus" growth—consistently expanding revenue faster than the overall veterinary market by increasing the utilization of diagnostics per clinical visit. This thesis is currently being tested and refined in a complex post-pandemic macroeconomic environment. While the company faces headwinds regarding veterinary visit volumes, which have softened in the United States throughout 2024 and 2025 due to inflationary pressures and labor constraints, IDEXX has demonstrated remarkable resilience. The company continues to drive top-line growth through aggressive net price realization, a strategic mix-shift toward higher-value diagnostic panels, and the successful launch of transformative innovations such as the inVue Dx cellular analyzer and the Cancer Dx platform.
IDEXX’s business model is structurally partitioned into three segments, yet it is overwhelmingly defined by the Companion Animal Group (CAG), which generates the vast majority of revenue and operating profit. The CAG segment operates on a classic "razor-and-blade" mechanism: IDEXX places capital-intensive instruments in clinics—often at competitive rates or through long-term volume commitments—to secure high-margin, long-term recurring revenue streams from consumables (reagents, slides, cartridges) and reference lab utilization. This is complemented by smaller, cash-generative divisions in Water quality testing and Livestock, Poultry, and Dairy (LPD) diagnostics, which provide diversification and steady cash flows, helping to fund the high-velocity R&D engine required to maintain dominance in the companion animal sector.
Financially, the company exhibits the hallmarks of a high-quality compounder: robust Return on Invested Capital (ROIC), consistent Free Cash Flow (FCF) conversion exceeding net income, and a disciplined capital allocation strategy focused on organic reinvestment and systematic share repurchases. In the third quarter of 2025, IDEXX reported earnings per diluted share (EPS) of $3.40, an increase of 21% as reported, signaling strong operational leverage even amidst a muted volume environment. The management team, led by CEO Jay Mazelsky, has raised full-year 2025 guidance, projecting revenue between $4.27 billion and $4.30 billion, and has outlined a clear trajectory for continued margin expansion.
However, the core tension for the sophisticated investor lies in the valuation. IDEXX rarely trades at a discount; its valuation multiple typically reflects a "scarcity premium" awarded to companies with monopolistic market shares and recession-resistant demand profiles. Trading at price-to-earnings (P/E) multiples that frequently exceed 50x, the stock leaves little margin for error in execution or macroeconomic deceleration. The continued consolidation of the veterinary industry—exemplified by aggressive moves from competitors like Zoetis and the vertical integration of Mars Petcare—presents a distinct long-term threat to IDEXX’s independent ecosystem.
This report provides an exhaustive analysis of IDEXX’s strategic positioning, financial health, and future prospects. It dissects the nuances of the competitive landscape, models the financial impacts of varying macroeconomic scenarios over the next five years, and evaluates the quality of earnings in the context of recent litigation and tax adjustments. The analysis concludes that while IDEXX remains a best-in-class asset with a long runway for international expansion, the current valuation necessitates a rigorous understanding of the risks associated with labor shortages and diagnostic maturity in the U.S. market.
To understand the investment viability of IDEXX, one must look beyond the surface-level metrics of revenue and earnings and deconstruct the structural drivers that power its growth engine. The company’s strategy is not merely to sell products but to embed itself into the clinical workflow so deeply that removal becomes operationally catastrophic for the veterinary practice. This section analyzes the core components of this strategy: the recurring revenue ecosystem, the innovation pipeline, the software moat, and the international expansion trajectory.
The Companion Animal Group (CAG) is the primary value driver, and its performance is best understood through the lens of "CAG Diagnostics Recurring Revenue." This metric, which excludes low-margin instrument sales, represents the annuity stream of consumables and reference lab services. In Q3 2025, this segment grew 8.3% on a reported basis and 7.5% organically, a testament to the stickiness of the platform.
The Razor-and-Blade Dynamics: The fundamental mechanism of IDEXX’s dominance is the placement of "hubs" within the clinic. These hubs are the diagnostic analyzers—specifically the Catalyst (chemistry), ProCyte (hematology), and SediVue (urinalysis) platforms.
Placement Strategy: IDEXX utilizes the largest direct sales force in the industry to place these instruments. Unlike a traditional hardware sale, these placements are often structured as "reagent rental" agreements or heavily discounted capital sales tied to long-term consumable contracts. This lowers the barrier to entry for the veterinarian while locking in future cash flows.
Utilization Growth: Once an instrument is installed, IDEXX’s growth algorithm depends on increasing "testing frequency" and "panel utilization." By educating veterinarians on the medical necessity of comprehensive bloodwork for both sick and healthy animals, IDEXX drives higher consumable usage per instrument.
Ecosystem Lock-in: The data generated by these instruments flows directly into the IDEXX VetLab Station (IVLS), a central hub that integrates results from all in-clinic analyzers and the reference laboratories. This unified patient report is a critical clinical tool. A clinic using IDEXX analyzers and reference labs has a seamless data experience; switching one component to a competitor (like Zoetis or Heska) breaks this integration, creating data silos and workflow friction. This high switching cost is the primary source of IDEXX’s pricing power.
IDEXX does not rely solely on price increases to drive growth; it creates new markets through technological innovation. The 2024-2025 period has seen the launch of several pivotal products designed to address specific industry pain points, particularly the labor shortage.
1. The inVue Dx Cellular Analyzer: Launched in late 2024 and ramping up significantly in 2025, the inVue Dx platform represents a paradigm shift in veterinary cytology. Historically, examining blood smears or ear swabs required a skilled technician to prepare a slide and a veterinarian to spend valuable time at a microscope.
The Solution: The inVue Dx automates this process using slide-free imaging technology. It provides reference-lab-quality images and AI-driven interpretation at the point of care.
Strategic Implication: This device directly addresses the technician shortage by automating a labor-intensive task. It allows clinics to bill for cytology services that they previously might have skipped due to time constraints. In Q3 2025 alone, IDEXX placed over 1,750 inVue Dx units, signaling rapid market acceptance and establishing a new layer of recurring revenue.
2. Oncology Expansion (Cancer Dx): In early 2025, IDEXX launched the Cancer Dx panel, a liquid biopsy screening tool for canine lymphoma.
Market Expansion: Oncology diagnostics have historically been the domain of specialized pathologists or invasive biopsies. By bringing a blood-based screening tool to the general practitioner, IDEXX is expanding the Total Addressable Market (TAM).
Revenue Quality: These are high-complexity, high-value tests processed at reference laboratories, which carry accretive margins and further utilize the company's logistical network.
3. Preventative Care and the "Wellness" Shift: A core tenet of IDEXX’s long-term strategy is shifting diagnostics from "reactive" (sick animal) to "proactive" (wellness visits). The company promotes the inclusion of SDMA (Symmetric Dimethylarginine), a proprietary kidney function marker, in routine wellness panels. This strategy decouples revenue growth from pet sickness rates, theoretically making the business more durable. However, this discretionary spending is also more sensitive to consumer wallet pressure, a dynamic currently playing out in the flat visit volume trends of 2025.
While diagnostics generate the revenue, software builds the wall around the customer. IDEXX’s portfolio of Practice Information Management Systems (PIMS)—including Cornerstone, eAVImark, and the cloud-native Neo—serves as the operating system for the clinic.
Integration: These software platforms manage scheduling, billing, and medical records. Crucially, they feature bi-directional integration with IDEXX diagnostic equipment. When a vet orders a test in the software, the analyzer automatically prepares; when the test is done, the result populates the record.
Competitive Defense: Competitor Zoetis has recognized this threat and aggressively acquired PIMS providers, but IDEXX remains the incumbent leader. The high friction of changing software systems (data migration, staff retraining) ensures that once a clinic is on an IDEXX software platform, they are highly unlikely to switch their diagnostic provider.
Customer Overlap: As of 2024, approximately 34% of U.S. customers utilized both IDEXX reference labs and in-house chemistry platforms, a figure that has grown by 300 basis points since 2022. IDEXX aims to push this "dual-modality" usage higher, as these "all-in" customers generate significantly higher lifetime value.
The United States market is mature, with high levels of diagnostic utilization ("medicalization"). The international market, however, remains fragmented and under-penetrated, offering a significantly longer runway for growth.
Performance: In Q3 2025, international regions delivered double-digit organic revenue growth, significantly outpacing the single-digit growth in the U.S..
Strategy: IDEXX is replicating its U.S. model in key markets like Germany, the UK, Japan, and Brazil. This involves building out reference laboratory networks to support direct sales efforts.
Challenges: International markets often have lower pet owner willingness-to-pay and different veterinary structures (more fragmented, fewer corporate consolidators). However, IDEXX’s success in growing premium instrument placements abroad suggests that the "standard of care" export strategy is working. The 71% organic growth in CAG instrument revenues in Q3 2025 was heavily supported by international adoption.
While comprising a smaller portion of total revenue, the Water and LPD (Livestock, Poultry, Dairy) segments are vital to the corporate structure.
Water: IDEXX is the global leader in microbiological testing for water safety. This business is highly regulated and incredibly stable, providing a steady cash flow "ballast" that is uncorrelated with the pet economy. In Q3 2025, the Water business grew 7% organically.
LPD: This segment faces cyclical challenges related to herd sizes and milk prices but remains profitable. In Q3 2025, LPD surprised to the upside with 14% gains, driven by specific disease outbreaks or regulatory testing requirements.
The financial profile of IDEXX in the 2024-2025 period reflects a company successfully pivoting from pandemic-era volatility to sustainable, albeit slightly more moderate, long-term growth. The analysis below dissects the income statement, balance sheet, and cash flow characteristics to determine the quality of earnings.
Fiscal Year 2024 Review: The fiscal year 2024 was characterized by solid top-line growth obscured by significant non-operational noise.
Revenue: Total revenue reached $3.898 billion, a 6.46% increase over 2023. This growth was driven by price realization and the resilience of the recurring revenue model.
The Litigation Impact: 2024 operational results were heavily impacted by a discrete litigation expense accrual of approximately $61.5 million recorded in Q2 2024. This creates a challenging comparison for GAAP metrics but highlights the importance of analyzing "comparable" or non-GAAP figures to understand the true operating power of the business. This accrual reduced full-year 2024 EPS by approximately $0.56 per share.
Contract Resolution: The year also included a negative growth impact from lapping a 2023 customer contract resolution payment, further muddying the growth optics.
Fiscal Year 2025 (Year-to-Date & Guidance): Moving into late 2025, the financial picture has clarified and strengthened. The Q3 2025 results demonstrate a return to form, with the company successfully navigating the "normalization" of the veterinary sector.
| Metric | Q3 2025 Actual | YoY Change (Reported) | YoY Change (Organic) | Context |
| Total Revenue | $1.105 Billion | +13.3% | +12% | Beat consensus estimates; broad-based strength across CAG and LPD. |
| CAG Recurring Rev. | -- | -- | +7.5% | Driven by net price realization and mix shift, offsetting soft visit volumes. |
| EPS (Diluted) | $3.40 | +21% | +15% (Comparable) | Strong operating leverage and tax benefits. |
| Operating Margin | 31.6% - 31.8% (FY Est) | -- | +50-80 bps (Comp) | Benefiting from gross margin expansion and OpEx discipline. |
Table Source Data:
2025 Full Year Outlook: Management has raised guidance consistently throughout 2025.
Revenue Guidance: $4.27 billion - $4.30 billion (Approx. 9.6% - 10.3% reported growth).
EPS Guidance: $12.81 - $13.01.
Key Insight: The projected revenue growth acceleration from 2024 (6.5%) to 2025 (~10%) confirms that IDEXX has successfully successfully passed through substantial price increases without breaking demand, a key indicator of a wide moat.
IDEXX benefits from a dual-layer margin expansion story.
Gross Margin Expansion: As the installed base of instruments grows, high-margin consumables become a larger percentage of the revenue mix. Reference lab volume growth also drives leverage on fixed lab costs (labor, facilities).
Operating Margin Expansion: The company targets 50-100 basis points of annual comparable operating margin improvement. In 2025, this is being achieved despite inflationary pressure on wages, indicating that pricing power is exceeding cost inflation. The 2025 guidance implies an operating margin approaching 32%, an elite figure for a hardware-intensive business.
Tax Considerations: It is important to note that EPS in 2025 benefited from a lower effective tax rate due to share-based compensation tax benefits ($0.17 per share in Q3 alone). Investors should strip this out when modeling long-term earnings power to avoid overestimating core profitability.
IDEXX maintains a "fortress" balance sheet that supports its premium valuation.
Leverage: The company typically maintains a Net Debt to Adjusted EBITDA ratio below 1.5x, providing ample dry powder for strategic maneuvers.
ROIC: Return on Invested Capital is a primary internal metric for executive compensation, ensuring capital is deployed efficiently. ROIC typically exceeds 30%, far above the cost of capital.
Share Repurchases: IDEXX is a "cannibal" of its own shares. Since 2015, the company has allocated over $5.1 billion to share repurchases, reducing the share count by over 47% since 1999. In 2025 alone, the outlook assumes approximately $1.5 billion in share repurchases. This systematic reduction of the denominator is a critical component of the long-term EPS growth algorithm (15-20% target).
Dividend Policy: IDEXX does not pay a dividend, preferring to reinvest in high-ROIC R&D or buy back stock. This is appropriate given the high returns available on internal capital deployment.
As of November 2025, IDEXX trades at approximately $697 per share.
P/E Ratio: Based on the midpoint of 2025 guidance ($12.91), the stock trades at a forward P/E of approximately 54x.
Historical Context: The 5-year average P/E ratio for IDEXX is roughly 54-55x. Consequently, the current valuation is strictly in line with its historical average.
Peer Comparison:
Zoetis (ZTS): Typically trades at 30-35x earnings.
Medical Device Peers: Typically trade at 25-30x earnings.
The Premium Justification: The market affords IDEXX this massive premium (nearly double the S&P 500 multiple) due to the predictability of its recurring revenue and the secular "pet humanization" tailwind. However, a 54x multiple implies that the market expects double-digit earnings growth to persist essentially forever. Any deterioration in the "15-20% EPS growth" algorithm puts the stock at risk of significant multiple compression.
While IDEXX is often viewed as a defensive "all-weather" stock, the 2024-2025 period has revealed specific vulnerabilities that must be factored into any risk model.
The most immediate and pressing risk is the decoupling of diagnostic revenue from veterinary visit volumes.
The Data: Piper Sandler surveys and industry reports from 2025 indicate that veterinary visit volumes have softened significantly. Industry growth is projected at just 3% in 2025, well below the historical 6% average. Consolidators report "softness in client visits" and "tempered pricing optimism."
The Mechanism: Inflation has strained the consumer wallet. While pet owners are reluctant to cut spending on their animals, there is a breaking point. The rapid rise in veterinary costs (driven by both labor inflation and IDEXX’s own pricing) may be causing consumers to delay "wellness" visits or decline optional diagnostic panels.
Implication: If volume growth turns consistently negative (-1% to -2%), IDEXX must rely entirely on price and mix to drive growth. This is sustainable in the short term but precarious in the long term; eventually, you cannot squeeze more revenue out of fewer customers without damaging the ecosystem.
The era of fragmented competition is over. IDEXX now faces two sophisticated, well-capitalized giants.
Mars Petcare (The Vertical Integrator): Mars is not just a candy company; it is the largest veterinary hospital owner in the world (Banfield, VCA, BluePearl). Mars has acquired Antech (reference labs) and Heska (point-of-care diagnostics).
The Risk: Mars has a massive financial incentive to force its thousands of hospitals to switch from IDEXX to Antech/Heska. While IDEXX currently maintains high retention even in Mars-owned clinics due to product superiority, "corporate capture" represents a hard ceiling on IDEXX’s addressable market within the corporate consolidation segment.
Zoetis (The Pharma Bundler): Zoetis is the leader in animal pharmaceuticals. It has aggressively entered the diagnostics space via the acquisition of Abaxis and the launch of competitive products like the Vetscan OptiCell (a direct competitor to IDEXX’s inVue Dx) and the Imagyst AI platform.
The Risk: Zoetis can bundle its "must-have" drugs (like Apoquel or Cytopoint) with diagnostic contracts to undercut IDEXX on price. While IDEXX has resisted this pressure so far through innovation, the gap in technology between IDEXX and Zoetis is narrowing.
The veterinary industry is suffering from a chronic, structural shortage of veterinarians and technicians.
The Bottleneck: If clinics cannot find staff, they must reduce operating hours or cap patient intake. This places a physical limit on the number of diagnostic tests that can be ordered, regardless of consumer demand.
Burnout: 60% of professionals expect hiring to remain difficult in 2025, and burnout is a dominant theme in industry surveys.
Mitigation: IDEXX argues that its automation tools (like inVue Dx) are the solution to this problem. However, in the short term, labor shortages are a net negative for volume.
IDEXX is subject to various legal proceedings, including a "now-concluded litigation matter" that impacted 2024 financials significantly ($61.5 million accrual). While this specific issue is resolved, the litigious nature of the competitive environment (patent disputes with competitors) remains a persistent low-level threat. Furthermore, regulatory scrutiny on veterinary pricing and consolidation (similar to human healthcare antitrust concerns) could eventually target the dominant players in the space.
The following analysis projects the total return profile for IDEXX through year-end 2030. These projections utilize the 2025 guidance midpoint as the Year 0 baseline and apply varying assumptions regarding macro conditions, competitive retention, and innovation adoption.
Baseline Inputs (Year 0 - 2025 Estimates):
Share Price: $697.00
2025 Estimated EPS: $12.91
Current P/E: ~54x
Shares Outstanding: ~81.8 Million (factoring in ongoing buybacks)
Narrative: The "pandemic puppy" cohort (pets acquired in 2020-2021) enters their geriatric years (age 7+), which is the prime window for high-intensity diagnostics. This demographic wave drives a structural increase in testing volume. The inVue Dx and Cancer Dx products achieve ubiquitous adoption, becoming standard-of-care. International markets accelerate as the "standard of care" export strategy succeeds in Asia and Europe. Macro conditions improve, allowing IDEXX to pass through 4-5% annual price increases while visit volumes return to healthy 2-3% growth.
Fundamentals:
Revenue CAGR: 12% (Driven by double-digit international growth & new tech).
Net Margin Expansion: Aggressive expansion to 26% via operating leverage.
Share Buybacks: 2.5% annual reduction in float (aggressive capital return).
Terminal Multiple: 55x (Market maintains the "Quality Premium" due to growth acceleration).
2030 Projected Financials:
Est. Revenue: ~$7.55 Billion.
Est. EPS: ~$26.50.
Implied Share Price: $1,457.
Narrative: IDEXX executes well on its strategic goals, but macro headwinds persist. Veterinary visit volumes remain flat (0-1%), meaning growth is driven almost entirely by price (3-4%) and mix shift (3-4%). New products succeed but partially cannibalize older modalities. International growth remains steady but does not accelerate significantly. The Mars/Zoetis competition effectively walls off a portion of the corporate market, limiting share gains.
Fundamentals:
Revenue CAGR: 9% (Meeting the lower end of long-term guidance).
Net Margin Expansion: Moderate expansion consistent with historical trends (50 bps/year).
Share Buybacks: 1.5% annual reduction.
Terminal Multiple: 45x (Slight compression as the company matures and growth slows).
2030 Projected Financials:
Est. Revenue: ~$6.60 Billion.
Est. EPS: ~$21.80.
Implied Share Price: $981.
Narrative: A prolonged consumer recession causes a contraction in veterinary visits (-2% annually). Pet owners trade down from premium diagnostics, rejecting optional panels. High inflation forces IDEXX to raise wages, compressing margins. Zoetis successfully commoditizes point-of-care diagnostics with cheaper alternatives. The market "de-rates" the stock, viewing it as a mature industrial company rather than a high-growth technology platform.
Fundamentals:
Revenue CAGR: 4% (Stagnation; price increases barely offset volume loss).
Net Margin: Flat or slight compression due to negative operating leverage.
Share Buybacks: 0.5% (Cash preserved for operations or debt service).
Terminal Multiple: 30x (Severe multiple compression to medical device peer averages).
2030 Projected Financials:
Est. Revenue: ~$5.2 Billion.
Est. EPS: ~$15.50.
Implied Share Price: $465.
The following table summarizes the potential outcomes. The "Base" case is given the highest probability (50%) as IDEXX has a long history of navigating difficult environments, but the "Bear" case (30%) is weighted higher than the "Bull" case (20%) due to the starting valuation risk.
Probability Weighted Price Target (2030): $921.30
Summary: PERFECTION PRICED IN. The analysis suggests a probability-weighted upside of approximately 32% over 5 years, resulting in a CAGR of roughly 5.7%. This underperforms the historical return of the S&P 500. While the Base and High cases offer respectable returns, the Low case highlights the significant asymmetry of risk posed by the current high valuation multiple. If the multiple compresses to 30x—a standard valuation for a slow-growth medical device company—the stock could lose a third of its value even if the company remains profitable.
This scorecard evaluates the intangible factors that contribute to IDEXX’s long-term durability.
| Metric | Score (1-10) | Narrative |
| Management Alignment | 10/10 | Executive alignment is exemplary. The CEO is required to hold shares worth 10x his base salary, and Executive VPs must hold 4x. Equity awards vest over four years, ensuring long-term focus. The board recently elected Jay Hooley, adding strategic depth. |
| Revenue Quality | 10/10 | The "razor-and-blade" model generates highly predictable, high-margin recurring revenue. The high switching costs associated with the integrated software/hardware ecosystem make this revenue extremely sticky, even in economic downturns. |
| Market Position | 10/10 | IDEXX is the undisputed leader. While Mars and Zoetis are formidable threats, IDEXX sets the global standard for innovation and possesses the deepest install base and data moat in the industry. |
| Growth Outlook | 7/10 | While secular trends (pet humanization) are strong, the law of large numbers and current visit volume headwinds limit the growth ceiling. Double-digit organic growth is becoming mathematically harder to achieve as the base expands. |
| Financial Health | 9/10 | The balance sheet is pristine. Leverage ratios are conservative (typically <1.5x Net Debt/EBITDA). Free cash flow generation is elite, consistently exceeding 100% of Net Income. |
| Business Viability | 10/10 | Veterinary care is an essential service. The business is immune to technological obsolescence in the near term; pets will always need bloodwork and diagnostics, and IDEXX owns the workflow. |
| Capital Allocation | 9/10 | Exceptional discipline. Management avoids "empire building" M&A, focusing instead on high-ROI internal R&D and systematic share buybacks ($5.1B returned since 2015). |
| Analyst Sentiment | 6/10 | Sentiment is generally positive ("Moderate Buy"), but price targets are often chasing the stock rather than leading it. There is little "contrarian" value here; the market is well aware of the company's quality. |
| Profitability | 9/10 | Gross margins and operating margins are expanding. The business model scales naturally; adding more tests to an existing lab network costs very little in incremental OpEx. |
| Track Record | 10/10 | IDEXX has been one of the best-performing stocks of the last two decades, consistently compounding value and navigating crises (2008 Financial Crisis, COVID-19) with agility. |
Overall Blended Score: 9.0/10
Summary: ELITE QUALITY COMPOUNDER
IDEXX Laboratories represents the gold standard in the animal health industry. The company possesses a rare combination of a monopolistic competitive moat, a recurring revenue model that behaves like a software business, and a management team that has proven its ability to allocate capital efficiently over decades. The strategic pivot toward automation—exemplified by the inVue Dx—and the expansion into high-complexity oncology testing with Cancer Dx provide a credible pathway for increasing revenue per clinical visit. This "revenue density" is the critical lever needed to offset the current stagnation in veterinary visit volumes.
However, the investment case is complicated by valuation. At ~54x forward earnings, the market has priced in a scenario of flawless execution. The asymmetry of the risk profile is skewed; the upside relies on continued multiple maintenance (the "greater fool" theory applied to quality stocks), while the downside involves a painful de-rating if growth decelerates to the mid-single digits. The consolidation of the industry by Mars and Zoetis introduces a long-term structural cap on market share that did not exist a decade ago.
Investment Verdict: Investors with a long-term horizon (5+ years) can likely rely on IDEXX to grow into its valuation through compounding earnings and aggressive buybacks, as reflected in the Base Case target of $981. The company is a core holding for any "quality growth" portfolio. However, new capital should be deployed cautiously. The company is a "Hold" for existing owners enjoying the compound growth, but prospective buyers should wait for a pullback to the 35-40x earnings range (approx. $450-$500/share) to establish a margin of safety. The primary catalyst for a re-rating—either up or down—will be the stabilization of veterinary visit volumes in the U.S. throughout 2026.
Summary: QUALITY AT PREMIUM
As of late November 2025, IDXX is trading around $697, exhibiting a rising trend in the medium term.
Trend: The stock has recently broken out above its 20-day moving average ($673), signaling short-term bullish momentum. It is trading comfortably above its 200-day moving average ($668), confirming that the long-term uptrend remains intact despite recent volatility.
Momentum: The Relative Strength Index (RSI) is at approximately 61, indicating positive momentum without being critically overbought (over 70 is typically the warning zone).
Signals: The Moving Average Convergence Divergence (MACD) indicator has issued a buy signal, suggesting that the recent upward price action has strength behind it.
Outlook: The technical setup supports the fundamental view of a high-quality stock recovering from a consolidation period. Short-term traders may look for a test of resistance at the $716 level. If the stock holds above the $668 support (200-day MA), the bullish trend is likely to continue into year-end.
Summary: BULLISH TREND CONTINUES
View IDEXX Laboratories Inc (IDXX) stock page
Loading the interactive version of this report…